Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Similar Posts
Decision: Advertising Investigations: January 2026
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
MHRA publishes final Business Plan for 2023-2026 Corporate Plan
The new Business Plan sets out priorities for 2025–26: Protecting public safety and maintaining public trust; delivering efficient, predictable services through regulatory excellence; being an agile organisation that drives innovation; being a great place to work and providing excellent customer service.
Public advised to stop using some non-sterile alcohol-free wipes
UKHSA and MHRA are urging the public not to use 4 specified non-sterile alcohol-free wipe products due to the risk of infection associated with their use.
Breast implant associated anaplastic large cell lymphoma (BIA-ALCL)
Information for patients, public and healthcare professionals.
Aurum pre-filled syringes phased introduction of new 10ml CONNECT syringe barrel: Importance of selecting compatible needle-free connectors to minimise the risk of syringe blockage (DSI/2025/02)
Due to a phased introduction of the new 10ml CONNECT barrel design for the Aurum pre-filled syringes, the range of compatible needle free connectors (NFCs) differs between the established syringe barrel and the new syringe barrel. It is vital that healthcare professionals use compatible NFCs with Aurum pre-filled syringes to prevent delays to delivery of emergency medication.
Guidance: Medical devices: examples of reportable incidents
Examples of what manufacturers must report to the MHRA under the medical device vigilance system when incidents involving their devices occur in the UK.